May 8, 2007 - OBS Medical and Physio-Control Inc., a wholly-owned subsidiary of Medtronic Inc., announced they have entered into a strategic relationship to improve patient safety through medical information innovations in external defibrillation monitoring technologies.
Under this global strategic relationship, which was announced by both companies at the 3rd International Conference on Rapid Response Systems, Physio-Control will license OBS Medical's BioSign technology to incorporate it into future monitoring and defibrillation products. The two companies will also collaborate in research for medical algorithms to better manage sudden cardiac arrest.
"We are excited to enter into this strategic relationship with Physio-Control, a pioneer and innovator in the global external defibrillation marketplace," said Frank Cheng, president and CEO of OBS Medical. "This is a major step toward ensuring better patient safety in and outside of hospitals. By integrating the BioSign algorithm with Physio-Control's future defibrillation products, we hope to add significant clinical insights for better assessment of patients' clinical conditions, and enable doctors and nurses to identify and respond to critically ill patients more effectively."
"This new strategic relationship is especially exciting to us as we create monitoring and resuscitation solutions for the future," said Brian Webster, president of Physio-Control. "OBS Medical's technology, the BioSign Index, will provide hospital and other clinicians, such as emergency medical services professionals, with an early warning index enabling them to more quickly respond in urgent medical situations when time is of the essence."
July 02, 2024 
